Back to Search
Start Over
Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients
- Source :
- Journal of Pediatric Surgery. 54:2162-2165
- Publication Year :
- 2019
- Publisher :
- Elsevier BV, 2019.
-
Abstract
- Limited knowledge exists as to what impact preoperative biologic therapy has on postoperative complications in pediatric patients undergoing abdominal surgery for Crohn's disease (CD). Therefore, we sought to determine the 30-day postoperative infectious complication rate among pediatric CD patients who received biologic therapy within 12 weeks of an abdominal operation.A retrospective chart review was performed on pediatric (18 years of age) CD patients who underwent an abdominal operation between 1/1/2008 and 12/31/2017. Patients were grouped according to whether they received an anti-TNF (infliximab, adalimumab, certolizumab pegol) or no biologic therapy within 12 weeks prior to the operation. The primary outcome was the overall 30-day postoperative infectious complication rate. Secondary outcomes included 30-day readmission rate and return to the operating room (ROR).A total of 69 pediatric CD patients met inclusion criteria (n = 54 anti-TNF therapy, n = 15 received no biologic therapy). There were no differences between the anti-TNF and no biologic cohorts with respect to demographics or CD characteristics. No significant differences in overall 30-day postoperative infectious complications existed between patients exposed to anti-TNF agents and those with no preoperative exposure, or in its subcategories of surgical infectious complications and nonsurgical infectious complications. There was also no difference in the rate of ileus, readmission, or ROR.Preoperative exposure to anti-TNF biologic therapy does not add to overall or infectious 30-day postoperative morbidity in pediatric CD patients.III.Retrospective review.
- Subjects :
- Male
Reoperation
medicine.medical_specialty
Adolescent
Ileus
Disease
Patient Readmission
Vedolizumab
03 medical and health sciences
Postoperative Complications
0302 clinical medicine
Crohn Disease
Gastrointestinal Agents
030225 pediatrics
Internal medicine
Ustekinumab
medicine
Humans
Surgical Wound Infection
Postoperative Period
Child
Retrospective Studies
Crohn's disease
business.industry
Adalimumab
General Medicine
Evidence-based medicine
medicine.disease
Infliximab
030220 oncology & carcinogenesis
Preoperative Period
Pediatrics, Perinatology and Child Health
Female
Tumor Necrosis Factor Inhibitors
Surgery
Tumor necrosis factor alpha
Immunotherapy
Morbidity
business
Intestinal Obstruction
Abdominal surgery
medicine.drug
Subjects
Details
- ISSN :
- 00223468
- Volume :
- 54
- Database :
- OpenAIRE
- Journal :
- Journal of Pediatric Surgery
- Accession number :
- edsair.doi.dedup.....2681395df86884f4e6817e4827f5741b